The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
This partnership has led to a 10% boost in delivery speed
Subscribe To Our Newsletter & Stay Updated